Dreaming of normoglycaemia with fewer diet restrictions

The Lancet Diabetes and Endocrinology

Volumn 2, Issue 5, 2014, Pages 350-351

  Ruggenenti, Piero ^a,b   Remuzzi, Giuseppe ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; GLUCOSE; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; ANGIOTENSIN ANTAGONIST; CANAGLIFLOZIN; CREATININE; CYSTATIN C; DAPAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2;

ADD ON THERAPY; ALBUMINURIA; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; DIABETES MELLITUS; DIET RESTRICTION; DISEASE COURSE; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG RESPONSE; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL ASSESSMENT; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART PROTECTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; DIABETES MELLITUS, TYPE 2; FEMALE; MALE; RENAL INSUFFICIENCY, CHRONIC; GLUCOSURIA; HYPOGLYCEMIA; KIDNEY FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); WEIGHT REDUCTION;

BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84899957421     PISSN: 22138587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-8587(14)70002-6     Document Type: Note

References (10)

1. Neumiller JJ, White JR, Campbell RK Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010, 70:377-385.
2. Nalysnyk L, Hernandez-Medina M, Krishnarajah G Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab 2010, 12:288-298.
3. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375:2223-2233.
4. Gilbert RE Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?. Kidney Int 2013, published online Nov 20. http://dx.doi.org/10.1038/ki.2013.451.
5. Barnett AH, Mitha A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014, on behalf of the EMPA-REG RENAL trial investigators, published online Jan 24. http://dx.doi.org/10.1016/S2213-8587(13)70208-0.
6. Thomson SC, Rieg T, Miracle C, et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 2012, 302:R75-R83.
7. Cherney DZ, Perkins BA, Soleymanlou N, et al. The renal hemodynamic effect of SGLT2 inhibition in patients with type 1 diabetes. Circulation 2013, published online Dec 13. http://dx.doi.org/10.1161/CIRCULATIONAHA.113.005081.
8. Ruggenenti P, Cravedi P, Remuzzi G Mechanisms and treatment of CKD. J Am Soc Nephrol 2012, 23:1917-1928.
9. Remuzzi G, Ruggenenti P, Perna A, et al. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J Am Soc Nephrol 2004, 15:3117-3125.
10. Gaspari F, Ruggenenti P, Porrini E, et al. The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney Int 2013, 84:164-173.